Jazz Pharmaceuticals PTSD treatment fails to meet endpoints in phase 2 trial

Jazz Pharmaceuticals’ experimental PTSD treatment failed to meet the primary endpoint in a phase 2 trial, the company announced in a press release.
JZP150 is a small-molecule selective fatty acid amide hydrolase inhibitor, which was being evaluated for safety and efficacy in adults with PTSD. The multicenter, double-blind placebo-controlled, randomized trial tested two doses of JZP150: 4 mg and 0.3 mg.
At the end of a 12-week period, neither dose produced a statistically significant decrease from baseline in PTSD symptom severity, as measured by the Clinician Administered PTSD Scale.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart